Surprise

3 min read
Frame 4040.png

As we round out this earnings season, it's time to size up winners and losers. Stocks with the biggest upside are often the ones with the financial results no one expected.

Four times a year, U.S.-listed firms share their financial results. Investors pore over revenue, net income and the all-important earnings per share (EPS), treating those quarterly reports like scorecards to measure company performance.

But even if a company delivers record results or another billion-dollar quarter, it isn’t necessarily enough. It needs to beat Wall Street estimates. This season, 79% of S&P 500 companies have done just that – with the biggest beats coming from healthcare while most consumer discretionary stocks missed the mark.

Let’s start with the big one: Nvidia ($NVDA). The highly anticipated earnings release did not disappoint, with the firm reporting Q2 revenue of US$30.04b against US$28.68b expectations. Its EPS came in at US$0.68 vs. the US$0.65 consensus.

In addition, Nvidia announced a US$50b share buyback and shared Q3 revenue guidance of US$32.5b, also ahead of estimates. Despite the impressive numbers beating sky-high expectations, shares fell 6% in after hours trading.

As for the rest of the Magnificent Seven, the market really liked Alphabet’s ($GOOG) first-ever cash dividend announcement. Tesla’s ($TSLA) disappointing numbers? Not so much. 

Amazon ($AMZN) shares surged to a near record after both earnings and revenue beat analyst expectations. Meta’s ($META) US$5.16 EPS also came in ahead of consensus and sent shares higher. And Apple ($AAPL) rewarded shareholders by not only beating EPS and revenue expectations, but also upping its dividend by 4% and announcing a US$110b share buyback – the largest on record. 

Healthcare favourite Eli Lilly’s ($LLY) EPS of US$3.92 surpassed analyst calculations by 21%, and its stock price rose to an intraday record high. Sales of its moneymaker drug Mounjaro rose 215% YoY, prompting the firm to up its outlook for the year by US$3b.

Analysts weren’t expecting much from biopharma giant Bristol-Myers Squibb ($BMY) and revised EPS estimates down to US$1.59 for this quarter. That’s likely why the stock gained 8.2% after the firm reported an actual EPS of US$2.07.

On the other end of the spectrum, Starbucks ($SBUX) delivered financial results even lower than the Street’s bleak forecasts. The coffee shop chain reported a 6% decline in China sales along with a 6% dropoff in foot traffic. Unsurprisingly, it shed 16% off its share price the day after its earnings report.

Potato chips are no safer than coffee when household budgets get tight. PepsiCo ($PEP) reported 4% lower sales volumes for its Frito-Lays snacks over the quarter, which contributed to its mixed earnings report that sent shares lower on the day. French fry maker Lamb Weston ($LW) missed EPS estimates by 37.9%, attributing its FY24 challenges to a decreased  frozen potato demand. Its shares tumbled 27% – the S&P’s worst performer after sharing its results.

And let's not forget Temu parent, PDD Holdings ($PDD). Only a slight revenue miss sent the stock down 28% on the day of its quarterly results. That’s after the firm reported a 86% YoY revenue growth to US$13.36b. 

Earnings season is equal parts opportunity and volatility, and it's worth looking beyond the numbers to find out how sustainable those profits really are. But if there’s one thing that wasn't a surprise this time around, it's the fact that higher earnings were mostly driven by cost-cutting and not revenue. The picture could change quickly, though, in a scenario of lower rates. This quarter’s losers might just be the next one’s winners.


Subscribe

By subscribing, you agree to our Privacy Policy.

Footer


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.